Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis

Kunst, Heinke; Wickremasinghe, M; Wells, Athol U.; Wilson, Robert

doi:10.1183/09031936.06.00139005

Cited by 123 publications

(99 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 Table 1 (Table S1 for full table) shows the study and patient characteristics of studies on pulmonary NTM disease (n = 13) and studies on both pulmonary and extra-pulmonary NTM diseases combined (n = 4). Studies examined the following outcomes: HRQOL alone (n = 2), 21,22 comorbidities alone (n = 1), 23 mortality alone (n = 11), 20,[24][25][26][27][28][29][30][31][32][33] and both comorbidities and mortality (n = 3). 9,34,35 The earliest study date was 1990 while the remaining spanned from 2003 to 2014.…”

Section: Resultsmentioning

confidence: 99%

“…Eight originated from East Asia, namely, Taiwan (n = 5), but also Hong Kong, South Korea and Japan. Almost all studies were retrospective cohort studies except for two case-control studies 21,23 and two cross-sectional studies. 9,22 Mean patient age was predominately 65 years or older.…”

Section: Resultsmentioning

confidence: 99%

“…All examined different conditions: Aspergillus-related lung disease, 23 respiratory diseases and non-respiratory diseases, 9,34 and pulmonary TB diagnosed during follow-up. 35 Among bronchiectasis patients in tertiary care in the UK, Kunst 23 (n = 91) found the odds of Aspergillusrelated lung disease were fivefold greater in those with pulmonary NTM disease after controlling for age and lung function (odds ratio (OR) (95% CI): 5.1 (1.5-17.0)). In a 5% random sample of US Medicare beneficiaries (n > 2.3 million), Adjemian 34 found many comorbid conditions occurred more frequently in those with pulmonary NTM diagnostic codes than those without.…”

Section: Associated Comorbiditiesmentioning

confidence: 99%

See 2 more Smart Citations

Health‐related quality of life, comorbidities and mortality in pulmonary nontuberculous mycobacterial infections: A systematic review

et al. 2016

View full text Add to dashboard Cite

Nontuberculous mycobacterial (NTM) infections are increasing in disease frequency worldwide. This systematic review examines health-related quality of life (HRQOL), comorbidities and mortality associated with pulmonary NTM disease. We searched MEDLINE, EMBASE, CINAHL, Scopus Life Sciences, conference proceedings and Google (earliest date available to February 2015) for primary studies. Eligible studies compared populations with and without pulmonary NTM disease in high-income jurisdictions. We excluded studies on HIV/AIDS. All languages were accepted. Two reviewers followed MOOSE and PRISMA reporting guidelines and independently appraised quality using STROBE. All studies were summarized qualitatively regardless of quality. Of 3193 citations screened, we included 17 studies mostly from Taiwan (n = 5) and the USA (n = 4). Two studies assessed HRQOL; one assessed comorbidities, 11 assessed mortality, and three assessed multiple outcomes. Populations with pulmonary NTM reported significantly worse or similar HRQOL than the general population, depending on the instruments used. Some suggested greater prevalence of having bronchiectasis (n =2) and greater risk of developing pulmonary tuberculosis (n = 1). Most (n = 7) suggested no difference in mortality, although only one was agematched and gender-matched to the general population. Four suggested NTM populations had higher mortality-two of which compared with the general population and were deemed of high quality, while two compared with non-NTM patients from hospital. High clinical heterogeneity in study design may explain discordant results. Bias assessments and controlling for confounding were carried out poorly. No consistent trends were observed although there is suggestion of an increased health burden from respiratory diseases and increased mortality associated with pulmonary NTM disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Associated Comorbiditiesmentioning

confidence: 99%

See 1 more Smart Citation

Health‐related quality of life, comorbidities and mortality in pulmonary nontuberculous mycobacterial infections: A systematic review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Likewise, infections by several species including M. xenopi, M. kansasii and M. malmoense have been described in association with bronchiectasis plus Aspergillus lung disease including invasive disease and aspergilloma. Aspergillus was more common in patients having both NTM and bronchiectasis than among patients with bronchiectasis alone and the presence of Aspergillus appeared to adversely affect prognosis [67].…”

Section: Comorbid Conditionsmentioning

confidence: 99%

Pulmonary disease caused by nontuberculous mycobacteria

Weiss

Glassroth²

2012

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

“…CPA usually occurs in middle-aged and elderly patients, for whom the most common underlying disease is pulmonary tuberculosis (6,7). In addition, there is increasing evidence that nontuberculous mycobacterial (NTM) lung disease is an important underlying condition associated with CPA (7)(8)(9)(10)(11)(12), with some patients having CPA and coexisting NTM lung disease (12,13).…”

mentioning

confidence: 99%

Effect of Rifampin and Rifabutin on Serum Itraconazole Levels in Patients with Chronic Pulmonary Aspergillosis and Coexisting Nontuberculous Mycobacterial Infection

Moon

Park

Jeong

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

bWe investigated the effects of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis. Serum itraconazole concentrations were significantly lower in patients who received itraconazole with rifampin (median, 0.1 g/ml; P < 0.001) or rifabutin (median, 0.34 g/ml; P < 0.001) than those receiving itraconazole alone (median, 5.92 g/ml). Concomitant use of rifampin or rifabutin and itraconazole should be avoided in patients with chronic pulmonary aspergillosis and coexisting mycobacterial infections. Chronic pulmonary aspergillosis (CPA) is a slowly progressive pulmonary infectious disease secondary to local invasion by a species of Aspergillus, usually Aspergillus fumigatus (1, 2). Although the optimal therapeutic regimen and duration of treatment have not been established, long-term oral itraconazole is currently recommended as the primary treatment for CPA (3-5). CPA usually occurs in middle-aged and elderly patients, for whom the most common underlying disease is pulmonary tuberculosis (6, 7). In addition, there is increasing evidence that nontuberculous mycobacterial (NTM) lung disease is an important underlying condition associated with CPA (7-12), with some patients having CPA and coexisting NTM lung disease (12,13).Mycobacterium avium complex (MAC) is the most common etiology of NTM lung disease (14-16). Rifampin is recommended as part of a multidrug antibiotic regimen for the treatment of MAC lung disease (14-16). Rifampin is a potent inducer of hepatic cytochrome P450 enzymes, which in turn can accelerate the hepatic metabolism of antifungal agents. In this way, rifampin presents a practical challenge for choosing the appropriate antibiotics for treating CPA with coexisting NTM lung disease (17,18). Indeed, previous case reports have demonstrated that concurrent administration of rifampin with itraconazole can greatly reduce serum itraconazole concentrations (19)(20)(21)(22).Rifabutin has less severe drug-drug interactions than does rifampin and is used as a substitute for rifampin in the treatment of tuberculosis and NTM lung disease, especially for patients who are receiving medications that have unacceptable interactions with rifampin, such as antiretroviral agents (14, 23). Nevertheless, there are no published studies that evaluated the interaction between rifabutin and itraconazole. Thus, the objective of the present study was to investigate the effects of rifampin and rifabutin on serum itraconazole levels in patients with CPA and coexisting mycobacterial lung disease.This study was a single-institution retrospective review of 66 patients with CPA who were treated with oral itraconazole (Sporanox, Janssen Pharmaceutica) (200 mg twice daily) and for whom serum itraconazole concentrations were measured between January 2013 and June 2014. Peripheral venous sampling was performed prior to morning itraconazole administration to determine trough concentrations after at least 7 days of treatment.The serum concentrations of itraconazole and hydroxyl-itraconazole we...

show abstract

Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis

Cited by 123 publications

References 29 publications

Health‐related quality of life, comorbidities and mortality in pulmonary nontuberculous mycobacterial infections: A systematic review

Health‐related quality of life, comorbidities and mortality in pulmonary nontuberculous mycobacterial infections: A systematic review

Pulmonary disease caused by nontuberculous mycobacteria

Effect of Rifampin and Rifabutin on Serum Itraconazole Levels in Patients with Chronic Pulmonary Aspergillosis and Coexisting Nontuberculous Mycobacterial Infection

Contact Info

Product

Resources

About